单个阿尔茨海默病神经元的体内基因组变化
Michael B Miller1,2,3,4, August Yue Huang2,3,4, Junho Kim2,3,4,5
1Division of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nature
|April 21, 2022
概括
阿尔茨海默病 (AD) 加快神经元的体质DNA变化,与正常衰老不同. 这些基因组变化可能由氧化应激驱动,导致AD的神经退行和神经元功能障碍.
科学领域:
- 神经科学
- 遗传学
- 分子生物学
背景情况:
- 阿尔茨海默病的特征是神经退行,但神经元功能障碍和死亡的根本原因尚未完全理解.
- 在正常衰老过程中,神经元会积累体质突变,受遗传和环境因素的影响.
- 了解这些突变对于破译阿尔茨海默病的产生至关重要.
研究的目的:
- 研究患有或没有阿尔茨海默氏症的个体的神经元的体质DNA变化.
- 确定与阿尔茨海默病相关的突变模式.
- 探索AD神经元中基因损伤的机制.
主要方法:
- 单细胞全基因组测序319个神经元从前额皮层和海马.
- 对阿尔茨海默病患者的神经元和神经类型对照的神经元DNA变化的分析.
- 在受影响神经元中核酸氧化的现场评估.
主要成果:
- 与对照组相比,阿尔茨海默氏病的神经元呈现出更多的体质DNA变化,除了与年龄相关的变化 (签名A) 之外,具有不同的分子模式 (签名C).
- 签名C涉及特定的核酸变化 (例如,C>A),表明核酸氧化作用,观察到AD神经元增加.
- 突变会影响编码区域,可能导致细胞功能失调和蛋白质静态应激,有证据表明转录合修复参与.
结论:
- 阿尔茨海默病的发病包括神经元中DNA变化的异常积累,导致神经退化.
- 基因组损伤可能由氧化应激和转录影响,在AD神经元功能障碍和死亡中起着重要作用.
- 这些发现为阿尔茨海默病发展的分子级联提供了新的见解.
相关概念视频
Alzheimer's Disease: Overview
696
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
696
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
Alzheimer's Disease: Treatment
272
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
272


